Aigen Investment Management LP Sells 5,767 Shares of Immunocore Holdings plc (NASDAQ:IMCR)

Aigen Investment Management LP decreased its holdings in shares of Immunocore Holdings plc (NASDAQ:IMCR) by 35.0% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 10,704 shares of the company’s stock after selling 5,767 shares during the quarter. Aigen Investment Management LP’s holdings in Immunocore were worth $316,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of IMCR. Wellington Management Group LLP grew its stake in shares of Immunocore by 10.5% during the third quarter. Wellington Management Group LLP now owns 7,048,833 shares of the company’s stock valued at $219,430,000 after buying an additional 668,382 shares during the last quarter. Primecap Management Co. CA grew its stake in Immunocore by 26.7% in the third quarter. Primecap Management Co. CA now owns 2,472,020 shares of the company’s stock worth $76,954,000 after purchasing an additional 520,950 shares in the last quarter. Two Sigma Advisers LP grew its stake in Immunocore by 65.6% in the third quarter. Two Sigma Advisers LP now owns 757,700 shares of the company’s stock worth $23,587,000 after purchasing an additional 300,200 shares in the last quarter. Principal Financial Group Inc. grew its stake in Immunocore by 25.0% in the third quarter. Principal Financial Group Inc. now owns 546,318 shares of the company’s stock worth $17,007,000 after purchasing an additional 109,206 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA grew its stake in Immunocore by 27.6% in the third quarter. Massachusetts Financial Services Co. MA now owns 498,221 shares of the company’s stock worth $15,510,000 after purchasing an additional 107,656 shares in the last quarter. Institutional investors own 84.50% of the company’s stock.

Immunocore Stock Performance

Shares of IMCR opened at $29.80 on Friday. Immunocore Holdings plc has a 12 month low of $27.69 and a 12 month high of $66.00. The stock has a fifty day moving average price of $30.16 and a 200-day moving average price of $31.60. The company has a current ratio of 3.78, a quick ratio of 3.76 and a debt-to-equity ratio of 1.03. The firm has a market cap of $1.49 billion, a PE ratio of -31.37 and a beta of 0.79.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on IMCR. Mizuho cut Immunocore from an “outperform” rating to a “neutral” rating and dropped their price objective for the stock from $72.00 to $38.00 in a research note on Monday, November 11th. HC Wainwright reissued a “buy” rating and issued a $100.00 price objective on shares of Immunocore in a research note on Friday, February 28th. Morgan Stanley restated an “equal weight” rating and set a $35.00 target price on shares of Immunocore in a report on Friday. Finally, Needham & Company LLC restated a “buy” rating and set a $71.00 target price on shares of Immunocore in a report on Thursday, February 27th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $65.64.

About Immunocore

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.